The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
about
Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid CancerSialadenitis following low dose I-131 diagnostic thyroid scan with Thyrogen® (recombinant human thyroid stimulating hormone--thyrotropin alfa).2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerNovel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease.Differentiated Thyroid Cancer-Treatment: State of the Art.EVALUATION OF THYROID TO BACKGROUND RATIOS AND COMPARISON OF VARIOUS SCINTIGRAPHIC MEASUREMENTS AND THEIR CORRELATION TO SERUM T4 IN HYPERTHYROID CATS.A Clinical Trial of Optimal Time Interval Between Ablation and Diagnostic Activity When a Pretherapy RAI Scanning Is Performed on Patients With Differentiated Thyroid Carcinoma.131I therapy for 345 patients with refractory severe hyperthyroidism: Without antithyroid drug pretreatment.Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: a comparison of lesions with 18F-FDG-PET and MIBI images.Adverse Reactions to Radioiodine 131I Therapy of Goiter in West African Tertiary HospitalLung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer.Predicting tumour response.Higher body weight and distant metastasis are associated with higher radiation exposure to the household environment from patients with thyroid cancer after radioactive iodine therapy.Technical Note: Determination of individual thyroid clearance effective half-life with a common handheld electronic dosimeter.Iodine concentration calculated by dual-energy computed tomography (DECT) as a functional parameter to evaluate thyroid metabolism in patients with hyperthyroidism.Radioactive Iodine Therapy of Differentiated Thyroid Carcinoma: Redesigning the Paradigm.Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force.Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review.Dosing of radioactive iodine in end-stage renal disease patient with thyroid cancer.Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance studyReproducibility of radioactive iodine uptake (RAIU) measurements.Vitamins E and C Prevent DNA Double-strand Breaks in Peripheral Lymphocytes Exposed to Radiations from Iodine-131.Whole-remnant and maximum-voxel SPECT/CT dosimetry in 131 I-NaI treatments of differentiated thyroid cancer.Radioactive (131)Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting.Combining radioiodine and external beam radiation therapy: the potential of integrated treatment planning for differentiated thyroid cancer.BRAF V600E mutational status in pediatric thyroid cancer.Radioactive 131Iodine Body Burden and Blood Dose Estimates in Treatment for Differentiated Thyroid Cancer by External Probe Counting.
P2860
Q26744936-414950D6-A4D7-4068-8A82-1D225F465902Q30277985-7E69F6BA-D88F-4093-930E-E1DEEEBB3803Q30367068-E0935B1A-EAD5-4EE1-920D-50A501602F1BQ33561428-13379C2F-2A9A-45AB-ACBA-9807A9363829Q33839037-33F03840-2532-43FF-82B4-DDFE50D32B37Q35897706-B62FF899-BA17-4112-8F36-077A0D7C6900Q36194764-B637FBEE-5D02-4FAA-8B11-1D20E6D34384Q37071682-835FCEE2-7279-49AC-9050-8E8F0BBA31DCQ37273089-21DCC63D-D704-44AA-B36B-C6ACCF717DA6Q37400468-23902610-6CCD-4484-A89B-01AA288BA539Q37677047-88A95261-520D-4F8B-A15A-163DF77B3FBCQ38141699-A660B73E-8DB4-4D5D-92A7-FAD301DF0F99Q38600214-8DC5F800-FC94-4B84-8F8A-C3BD70BCB71FQ38958098-B9148A5B-0016-4536-AC95-A5F21CD5A9C6Q41065688-A6417B1E-8F8B-479D-A2ED-399ADB4F3611Q42233644-80F4FCAB-451D-49A0-819A-603D81F8D2A7Q47105571-00B1DA9E-E4B4-4571-B61D-39212338A528Q47124584-DCDE9ADB-1105-4DF9-A0C6-D0D45A372E98Q47134328-E25E8CD1-4EFD-4C94-AE6A-DCD11C0FA231Q47207716-C5D0AEEB-2CD1-4750-A490-38484E070E4FQ48968811-EE7E9A75-DCD0-44CC-90B6-4C2B43697DCEQ49805930-BA741F6A-2239-42B1-ABEC-8A9F2AABA886Q49812861-995E7F6A-C5BC-4403-B781-882D6B513EA1Q50943856-5FCDF30E-5CD6-4E87-8AC1-EA9C9AA01A71Q51800697-C3025687-5838-405A-802D-D943E58DDC8FQ53987356-4610B930-B626-42BD-8951-2A9E06C9C842Q54364096-0B8E8DB8-2F12-460D-A2A0-B8B851C4916BQ54612394-65DFD21C-3926-4442-B5F7-ECF43A5F76C9
P2860
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
description
im Juli 2012 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2012
@uk
name
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
@en
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
@nl
type
label
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
@en
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
@nl
prefLabel
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
@en
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
@nl
P2093
P1476
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
@en
P2093
A. D. Waxman
C. S. Marcus
E. B. Silberstein
H. D. Royal
H. R. Balon
J. A. Parker
M. J. Gelfand
P304
P356
10.2967/JNUMED.112.105148
P407
P577
2012-07-11T00:00:00Z